X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3329) 3329
Book Review (920) 920
Publication (365) 365
Newspaper Article (39) 39
Book Chapter (20) 20
Newsletter (13) 13
Book / eBook (10) 10
Conference Proceeding (10) 10
Magazine Article (6) 6
Dissertation (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2924) 2924
humans (1979) 1979
animals (1600) 1600
male (1155) 1155
pharmacology & pharmacy (855) 855
female (825) 825
potassium (701) 701
potassium channels (640) 640
rats (531) 531
cardiac & cardiovascular systems (476) 476
middle aged (455) 455
dose-response relationship, drug (395) 395
potassium channel blockers - pharmacology (359) 359
aged (357) 357
adult (325) 325
abridged index medicus (323) 323
hypertension (308) 308
neurosciences (300) 300
analysis (293) 293
physiology (283) 283
risk factors (270) 270
mice (264) 264
arrhythmia (244) 244
potassium channel (241) 241
electrocardiography (239) 239
drugs (230) 230
patch-clamp techniques (229) 229
heart (224) 224
in vitro techniques (215) 215
treatment outcome (213) 213
rats, sprague-dawley (212) 212
rodents (211) 211
ion channels (207) 207
electrophysiology (205) 205
action potentials - drug effects (203) 203
drug therapy (203) 203
mortality (203) 203
research (202) 202
time factors (201) 201
cardiac arrhythmia (198) 198
potassium channels - metabolism (198) 198
calcium (192) 192
peripheral vascular disease (191) 191
article (190) 190
potassium channel blockers - adverse effects (190) 190
potassium channels - drug effects (189) 189
pharmacology (186) 186
blood pressure (182) 182
disease models, animal (177) 177
toxicology (176) 176
care and treatment (174) 174
inhibition (174) 174
potassium channel blockers - therapeutic use (173) 173
potassium - blood (171) 171
hypertension - drug therapy (170) 170
rats, wistar (168) 168
potassium - metabolism (164) 164
biochemistry & molecular biology (163) 163
health aspects (163) 163
heart failure (163) 163
herg (162) 162
physiological aspects (161) 161
long qt syndrome - chemically induced (160) 160
double-blind (159) 159
cardiology (158) 158
studies (158) 158
medicine & public health (157) 157
blood pressure - drug effects (155) 155
cell biology (154) 154
potassium channel blockers (153) 153
blood-pressure (151) 151
erg1 potassium channel (151) 151
cells, cultured (148) 148
long qt syndrome (148) 148
clinical neurology (147) 147
channels (145) 145
ether-a-go-go potassium channels - antagonists & inhibitors (142) 142
activation (140) 140
anti-arrhythmia agents - pharmacology (140) 140
dogs (138) 138
anti-arrhythmia agents - therapeutic use (137) 137
cardiovascular (135) 135
proteins (135) 135
k+ channel (134) 134
medicine (133) 133
potassium channels - physiology (133) 133
membrane potentials - drug effects (132) 132
heart rate - drug effects (131) 131
heart - drug effects (130) 130
risk (130) 130
torsades de pointes - chemically induced (130) 130
calcium - metabolism (129) 129
channel (129) 129
torsades-de-pointes (129) 129
anti-arrhythmia agents - adverse effects (127) 127
expression (127) 127
patients (127) 127
arrhythmias, cardiac - chemically induced (126) 126
atrial fibrillation (126) 126
diuretics (125) 125
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3394) 3394
German (8) 8
Japanese (4) 4
Chinese (2) 2
French (2) 2
Danish (1) 1
Lithuanian (1) 1
Portuguese (1) 1
Russian (1) 1
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 11/2014, Volume 96, Issue 5, pp. 549 - 558
Journal Article
The Lancet, ISSN 0140-6736, 09/2005, Volume 366, Issue 9489, pp. 895 - 906
The apparent shortfall in prevention of coronary heart disease (CHD) noted in early hypertension trials has been attributed to disadvantages of the diuretics... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | MANAGEMENT | MORBIDITY | DISEASE | GUIDELINES | DOUBLE-BLIND | CALCIUM-ANTAGONISTS | HYPERTENSION | INTERVENTION | Calcium Channel Blockers - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Bendroflumethiazide - administration & dosage | Hypertension - drug therapy | Male | Perindopril - administration & dosage | Sodium Chloride Symporter Inhibitors - administration & dosage | Diuretics | Adrenergic beta-Antagonists - adverse effects | Adult | Female | Blood Pressure - drug effects | Atenolol - administration & dosage | Drug Therapy, Combination | Amlodipine - administration & dosage | Adrenergic beta-Antagonists - administration & dosage | Risk Factors | Amlodipine - adverse effects | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Coronary Disease - prevention & control | Calcium Channel Blockers - administration & dosage | Atenolol - adverse effects | Hypertension - complications | Aged | Hypertension | Antihypertensive drugs | Evaluation | Dosage and administration | Drug therapy | Prevention | Drug therapy, Combination | Health aspects | Coronary heart disease | Risk factors | Studies | Drugs | Cardiovascular disease | Medical treatment | Myocardial infarction | Heart attacks | Clinical trials | Family medical history | Blood | Randomization | Motivation | Blood pressure | Heart diseases | Antihypertensive agents | Cerebral infarction | Stroke | Fasting | Mortality | Diabetes mellitus | Health risks | Triglycerides | Metabolism | Risk analysis | Atenolol | Fatal | Patients | Coronary artery disease | Cholesterol | Heart rate | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Potassium | Index Medicus | Abridged Index Medicus | Amlodipine/administration & dosage/adverse effects | Bendroflumethiazide/administration & dosage | Cardiovascular Diseases/prevention & control | Perindopril/administration & dosage | MEDICIN OCH HÄLSOVETENSKAP | Atenolol/administration & dosage/adverse effects | Combination | Antihypertensive Agents/administration & dosage/adverse effects | Angiotensin-Converting Enzyme Inhibitors/administration & dosage | MEDICAL AND HEALTH SCIENCES | Coronary Disease/prevention & control | Drug Therapy | Adrenergic beta-Antagonists/administration & dosage/adverse effects | Blood Pressure/drug effects | Hypertension/complications/drug therapy | Calcium Channel Blockers/administration & dosage/adverse effects | Sodium Chloride Symporter Inhibitors/administration & dosage
Journal Article
Cardiovascular Research, ISSN 0008-6363, 7/2011, Volume 91, Issue 1, pp. 53 - 61
Journal Article
Toxicological Sciences, ISSN 1096-6080, 03/2017, Volume 156, Issue 1, pp. 25 - 38
Drug-induced proarrhythmia is a major safety issue in drug development. Developing sensitive in vitro assays that can predict drug-induced cardiotoxicity in... 
Drug-induced proarrhythmia | iPSC-CMs | Batch variations | ACTION-POTENTIALS | TORSADES-DE-POINTES | DOFETILIDE | CONTRACTILITY | drug-induced proarrhythmia | PROLONGATION | LONG-QT SYNDROME | VENTRICULAR MYOCYTES | MATURATION | IMPEDANCE | TOXICOLOGY | batch variations | RISK-ASSESSMENT | Arrhythmias, Cardiac - chemically induced | Drug Evaluation, Preclinical - economics | Calcium Channel Blockers - adverse effects | Anti-Arrhythmia Agents - pharmacology | Humans | Potassium Channel Blockers - antagonists & inhibitors | Toxicity Tests, Acute - methods | Potassium Channel Blockers - adverse effects | Arrhythmias, Cardiac - pathology | Shal Potassium Channels - genetics | Kv1.5 Potassium Channel - genetics | Toxicity Tests, Acute - economics | Induced Pluripotent Stem Cells - cytology | Voltage-Gated Sodium Channel Blockers - adverse effects | Potassium Channel Blockers - pharmacology | Induced Pluripotent Stem Cells - metabolism | Arrhythmias, Cardiac - metabolism | Induced Pluripotent Stem Cells - pathology | Cell Line | Drug Evaluation, Preclinical - methods | Reproducibility of Results | Induced Pluripotent Stem Cells - drug effects | Myocytes, Cardiac - cytology | Antioxidants - pharmacology | Calcium Channel Blockers - pharmacology | Gene Expression Regulation - drug effects | Myocytes, Cardiac - pathology | Shal Potassium Channels - metabolism | Calcium Channels, L-Type - genetics | Myocytes, Cardiac - drug effects | Cell Differentiation - drug effects | Kv1.5 Potassium Channel - metabolism | Calcium Channel Blockers - chemistry | Myocytes, Cardiac - metabolism | Voltage-Gated Sodium Channel Blockers - pharmacology | Calcium Channels, L-Type - metabolism | Kinetics | Electrophysiological Phenomena - drug effects | Index Medicus
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 02/2016, Volume 99, Issue 2, pp. 214 - 223
Journal Article
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 05/2010, Volume 160, Issue 1, pp. 60 - 76
Background and purpose:  The regulatory guidelines (ICHS7B) for the identification of only drug-induced long QT and pro-arrhythmias have certain limitations.... 
ventricular fibrillation (VF) | conduction time | INa | ventricular tachycardia (VT) | drug | I | Na | Drug | Conduction time | Ventricular fibrillation (VF) | Ventricular tachycardia (VT) | FIBRILLATION | FLECAINIDE | VENTRICULAR-TACHYCARDIA | MECHANISMS | PROLONGATION | SUDDEN UNEXPECTED DEATH | BRUGADA-SYNDROME | I-Na | LIDOCAINE | ACUTE MYOCARDIAL-INFARCTION | PHARMACOLOGY & PHARMACY | CHANNELS | Lidocaine - pharmacology | Lidocaine - adverse effects | Arrhythmias, Cardiac - chemically induced | Cricetulus | Myocardial Reperfusion Injury - chemically induced | Anti-Arrhythmia Agents - pharmacology | Tachycardia, Ventricular - chemically induced | Electric Conductivity | Sodium Channels - physiology | Purkinje Fibers - drug effects | Sodium Channel Blockers - adverse effects | Ventricular Fibrillation - physiopathology | Ether-A-Go-Go Potassium Channels - physiology | CHO Cells | Drug Evaluation, Preclinical - methods | Rabbits | Cricetinae | Sodium Channel Blockers - pharmacology | Flecainide - pharmacology | Heart Conduction System - drug effects | Myocardial Reperfusion Injury - physiopathology | Flecainide - adverse effects | Patch-Clamp Techniques | Tachycardia, Ventricular - physiopathology | Animals | Anti-Arrhythmia Agents - adverse effects | Ventricular Fibrillation - chemically induced | In Vitro Techniques | Purkinje Fibers - physiology | Sodium | Cardiac arrhythmia | Index Medicus | Research Papers | I Na
Journal Article
PloS one, ISSN 1932-6203, 2017, Volume 12, Issue 7, pp. e0180762 - e0180762
Journal Article